| Literature DB >> 15916709 |
Judith L Ngondi1, Julius E Oben, Samuel R Minka.
Abstract
Dietary fibres are frequently used for the treatment of obesity. The aim of this study was to evaluate the efficacy of Irvingia gabonensis seeds in the management of obesity. This was carried out as a double blind randomised study involving 40 subjects (mean age 42.4 years). Twenty-eight subjects received Irvingia gabonensis (IG) (1.05 g three time a day for one month) while 12 were on placebo (P) and the same schedule. During the one-month study period all subjects were on a normocaloric diet evaluated every week by a dietetic record book. At the end, the mean body weight of the IG group was decreased by 5.26 +/- 2.37% (p < 0.0001) and that of the placebo group by 1.32 +/- 0.41% (p < 0.02). The difference observed between the IG and the placebo groups was significant (p < 0.01). The obese patients under Irvingia gabonensis treatment also had a significant decrease of total cholesterol, LDL-cholesterol, triglycerides, and an increase of HDL-cholesterol. On the other hand, the placebo group did not manifest any changes in blood lipid components. Irvingia gabonensis seed may find application in weight lose.Entities:
Mesh:
Substances:
Year: 2005 PMID: 15916709 PMCID: PMC1168905 DOI: 10.1186/1476-511X-4-12
Source DB: PubMed Journal: Lipids Health Dis ISSN: 1476-511X Impact factor: 3.876
Effect Irvingia gabonensis on systolic (SBP) and diastolic (DBP) blood pressure
| Treatment period (weeks) | ||||
| 0 | 2 | 4 | ||
| SBP (mmHg) | Active | 136.41 ± 19.57 | 132.66 ± 18.48* | 132.83 ± 17.97* |
| Placebo | 134 ± 5.05 | 121.5 ± 5.89 | 123.83 ± 2.92 | |
| DBP (mmHg) | Active | 98.5 ± 19.52 | 97.5 ± 22.80 | 94.08 ± 11.07 |
| placebo | 93.50 ± 10.31 | 93.83 ± 7.41 | 91.5 ± 6.53 | |
Values are means ± sem. Significant differences were at *P < 0.001 by comparison to the placebo group.
Effect of Irvingia gabonensis crude extract on body weight, body fat, waist and hip circumferences
| Treatment period (weeks) | ||||
| 0 | 2 | 4 | ||
| Weight (kg | Active | 105.10 ± 16.98 | 102.3 ± 17.06 | 101.01 ± 16.63 |
| Placebo | 79.43 ± 9.83 | 79.43 ± 9.83 | 79.33 ± 10.63 | |
| Active | 46.11 ± 4.4848 | 46.5 ± 3.68 | 45.34 ± 3.52 | |
| Body fat (%) | Placebo | 40.58 ± 3.49 | 40.58 ± 3.9 | 40.3 ± 3.8 |
| Active | 112.76 ± 20.5 | 109.7 ± 20.4 | 106.6 ± 20.79 | |
| Waist (cm) | Placebo | 81.1 ± 7.1 | 81,91 ± 7,91 | 81.25 ± 7.52 |
| Active | 125.69 ± 11.34 | 122.92 ± 10.67 | 121.15 ± 10.39 | |
| Hip (cm) | Placebo | 122.2 ± 10.7 | 122.2 ± 10.7 | 121.5 ± 10.9 |
The effect of Irvingia gabonensis on blood total cholesterol (TC), triglyceride (TRI), high density lipoprotein cholesterol (HDL-c), low density lipoprotein cholesterol (LDL-c) and glucose.
| T-cholesterol | TRI | HDL-c | LDL-c | LDL/HDL | T-cho/HDL | GLUCOSE | ||
| Active | Initial | 215 ± 55.12 | 162 ± 33.15 | 61.23 ± 20.36 | 121.37 ± 36.3 | 1.98 ± 1.78 | 3.51 ± 2.70 | 3.8 ± 1.92 |
| Final | 130.68 ± 39.5 | 89.22 ± 55.63 | 89.9 ± 28.44 | 66.08 ± 34.27 | 0.735 ± 1.20 | 1.45 ± 1.38 | 2.57 ± 1.03 | |
| Placebo | Initial | 163.70 ± 25.32 | 130.65 ± 37.82 | 31.38 ± 25.21 | 105.06 ± 11.86 | 5.05 ± 3.94 | 6.44 ± 3.37 | 3.6 ± 0.41 |
| Final | 158.36 ± 30.46 | 100.52 ± 32.55 | 41.20 ± 19.53 | 98.55 ± 27.99 | 3.19 ± 1.85 | 4.51 ± 2.07 | 3.9 ± 0.74 |